-
Trump says to make delayed China trip in 'five or six weeks'
-
Kompany warns of complacency as injury-hit Bayern host Atalanta
-
Larijani: Iran power player who rose then fell on winds of war
-
SAS cancels flights after fuel prices surge
-
New particle discovered by Large Hadron Collider
-
Lebanon says Israeli strikes kill soldiers, as shelters overflow
-
Van de Ven insists it's 'nonsense' to say players don't care about Spurs' plight
-
Argentina withdraws from World Health Organization
-
US Fed expected to keep rates steady as Iran war impact looms
-
Two men in Kenyan court for ant-smuggling
-
Cuba scrambles to restore power as Trump threatens takeover
-
War fuels fears of new oil crisis
-
Kerr 'frustrated' at six-figure sum owed to him by Johnson's failed Grand Slam Track
-
Senior US counterterrorism official resigns to protest Iran war
-
In shadow of Iran war, Gazans prepare for Eid
-
Oil prices climb as fresh strikes target infrastructure
-
Southern Lebanon paramedics risk deadly Israeli strikes to do their work
-
Len Deighton, spy novelist who created the anti-Bond
-
Barca Flick's 'last job' but not yet certain on renewal
-
Belgian diplomat ordered to stand trial over 1961 Congo leader murder
-
Pope says idea England 'weren't fussed' about the Ashes was tough to take
-
War threatens Gulf's dugongs, turtles and birds
-
Germany targets oil firms to prevent wartime price gouging
-
Chelsea striker Kerr sends Australia into Asian Cup final
-
'East meets West': KPop Demon Hunters brings global fans to Seoul's sites
-
Israel says killed Iran's security chief Larijani
-
EU to help reopen blocked oil pipeline in Ukraine
-
Thai eSports players sentenced over SEA Games cheating scandal
-
Nigeria suicide bombings kill 23, wound more than 100
-
Iran's Larijani, the man whose power grew during Mideast war
-
Millions of Indonesians in Eid travel exodus
-
Israel strikes Beirut suburbs as displacement shelters overflow
-
Hard-hitting Conway steers New Zealand to victory over South Africa
-
During Ramadan, Senegal's Baye Fall community lives to serve
-
Russian ballet banned for 'gay propaganda' gets new life in Berlin
-
Strikes shake Tehran as Trump presses allies to help in Mideast war
-
Malaysia hit with 3-0 forfeits to send Vietnam to Asian Cup
-
Rescue workers comb ruins of Kabul drug clinic after Pakistan strike
-
'Many dead': Wounded survivor escaped Kabul clinic strike
-
Belgian court decides on holding trial over 1961 Congo leader murder
-
Kabul drug rehab clinic in ruins after Pakistan strikes on Afghanistan
-
Israel strikes Tehran, Beirut as Iraq pulled deeper into Mideast war
-
Georgia ready for rugby elite despite rare Portugal defeat
-
Doncic leads Lakers to sixth straight win, Spurs sink Clippers
-
Iran 'negotiating' with FIFA over moving World Cup games to Mexico: embassy
-
Gavaskar condemns Indian-owned franchise for signing Pakistan bowler
-
Cash handouts, fare hikes as Philippines battles soaring fuel costs
-
Alleged Bondi Beach killer's mother received death threats, court told
-
Venezuela end Italy fairytale to reach World Baseball Classic final
-
Sweden's prisons prepare to house young teens
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
A.Ammann--VB